Urovant Sciences (UROV) Reports Q2 Loss of $1.23

Urovant Sciences (NASDAQ: UROV) reported Q2 EPS of ($1.23).

“Urovant Sciences advanced several clinical programs for vibegron, an investigational beta-3 adrenergic agonist, demonstrating our commitment to urology,” said Keith A. Katkin, chief executive officer of Urovant. “We successfully enrolled more than 1,500 patients into our robust international Phase 3 trial evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of overactive bladder. We expect to report top-line data from this phase 3 study by the end of March 2019. In addition, we plan to initiate a Phase 2a study of vibegron in women with IBS-associated pain by the end of 2018. And finally, we had productive discussions with the FDA that culminated in us submitting a proposed protocol to study vibegron for men with overactive bladder with BPH.”

“I am immensely proud of my team’s momentum with vibegron,” added Katkin. “We also continue to assess business development opportunities that support our longer-term vision of becoming a leading urology company. We were pleased to have recently added the gene therapy hMaxi-K to our clinical development portfolio.”

For earnings history and earnings-related data on Urovant Sciences (UROV) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• First Bancshares (FBMS) Tops Q1 EPS by 6c
• Analysts favorite fintech stock Adyen tumbles after revenue miss